Title:Repurposing of Alexidine Dihydrochloride as an Apoptosis Initiator and Cell Cycle Inhibitor in Human Pancreatic Cancer
Volume: 20
Issue: 16
Author(s): Ezgi Kasikci, Esra Aydemir, Bekir M. Yogurtcu, Fikrettin Sahin and Omer F. Bayrak*
Affiliation:
- Department of Medical Genetics, Yeditepe University Medical School and Yeditepe University Hospital, Istanbul 34718,Turkey
Keywords:
Cancer, pancreatic adenocarcinoma, alexidine dihydrochloride, chemotherapy, apoptosis, cell cycle.
Abstract:
Background: Highly aggressive and resistant to chemotherapy, pancreatic cancers are the fourth
leading cause of cancer-related deaths in the western world. The absence of effective chemotherapeutics is leading
researchers to develop novel drugs or repurpose existing chemicals. Alexidine Dihydrochloride (AD), an
orally bioavailable bis-biguanide compound, is an apoptosis stimulating reagent. It induces mitochondrial damage
by inhibiting a mitochondrial-specific protein tyrosine phosphatase, PTPMT1. The aim of this study was to
test AD as a novel compound to induce apoptosis in a human pancreatic adenocarcinoma cell lines, Panc-1,
MIA PaCa-2, AsPC-1, and Psn-1.
Methods: After the IC50 value of the AD was determined by cytotoxicity assay, apoptosis was observed by a
variety of methods, including the detection of early apoptosis marker Annexin V and the proteomic profile
screening by apoptosis array. Multicaspase and mitochondrial depolarization were measured, and changes in the
cell cycle were analyzed.
Results: AD is found to initiate apoptosis by activating the intrinsic pathway and inhibit the cell cycle in pancreatic
cancer cell lines.
Conclusion: In conclusion, considering its anti-cancer properties and bioavailability, Alexidine dihydrochloride
can be considered as a potential candidate against pancreatic adenocarcinomas.